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A
n 18-year-old Caucasian male with type 1 diabetes 
presented to the emergency department complaining 
of severe left knee pain and swelling after sustaining 
a knee injury that occurred during a high school football 
match. Joint effusions were visible and palpable above the left 
knee, and there was signiﬁ  cant loss of smooth motion of the 
knee, passively performed. Plain X rays showed no signs of 
fractures. The patient had had type 1 diabetes for six years, 
and his insulin regimen consisted of insulin glargine, 35 units 
at 8:00 p.m., and insulin lispro, 23 units at 8:00 a.m. and 16 
units at 8:00 p.m. The patient had no apparent complications 
related to type 1 diabetes. 
On examination he was alert, his pulse was 76 bpm regular, 
and his blood pressure was 118/66 mm Hg. Recently, the 
patient had had frequent episodes of both hyperglycemia 
and hypoglycemia. However, he had never developed 
diabetic ketoacidosis (DKA). His recent HbA1c was 9.5%, 
demonstrating inadequate glycemic control. 
The patient was referred to an orthopedic surgeon, and 
arthroscopy was scheduled a few days later. A complex tear 
of the medial meniscus extending to the articular surfaces 
was diagnosed. Partial meniscectomy was recommended. 
(This procedure usually takes about one hour—nonetheless, 
the preoperative preparation for general anesthesia and the 
postoperative recovery may add several hours to this time.)
When Would You Have This Patient Report to the 
Hospital? The Day before Surgery or the Morning 
of Surgery?
This patient should be hospitalized no later than the evening 
before surgery, given his history of frequent episodes of 
hypo- and hyperglycemia and his poor glycemic control. 
This should allow for ﬁ  nal optimization of glucose control 
before surgery. Ideally, frequent contact with the patient and 
adjustment of the insulin regimen prior to surgery should 
lead to an excellent glycemic control. This 18-year-old patient 
on glargine might beneﬁ  t from additional doses of lispro 
given before lunch and dinner (rather than at 8 p.m., unless 
this is before dinner). 
A patient with poorly controlled diabetes should not 
undergo elective surgery until glycemic levels are reasonably 
controlled. For example, bringing the patient into the 
hospital with blood glucose levels of 450 mg/dl will likely 
result in a canceled surgery. If a patient is scheduled for 
day of admission surgery, one way to avoid having to send 
the patient out without being able to do the procedure is 
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DESCRIPTION of CASE Box 1. Management of Type 1 Diabetes during 
Minor Surgery Procedures 
Day of procedure if the patient is NPO:
• Withhold morning dose of insulin.
• Measure capillary glucose levels prior to procedure every 
2–4 hours.
• Administer short-acting or fasting insulin subcutaneously 
every 2–4 hours as indicated in Table 1.
• Administer the usual afternoon dose of insulin.
Day of procedure if breakfast is allowed:
• Administer morning dose of insulin.
• Measure glycemia before and after procedure.
• Give supplemental four units of short- or fast-acting insulin 
subcutaneously if glycemic levels are >250 mg/dl.
• Give usual afternoon insulin dose.
Modiﬁ  ed from [6].
Table 1. Administering Insulin during Minor Surgery 
Procedures
Blood Glucose Short- or Fast-Acting 
Insulin (Units) mg/dl mmol/l
≤150   ≤5.6 0
 151–200   5.6–11.1 2
 201–250   11.1–13.9 3
 251–300   13.9–16.7 5
≥300   ≥16.7 6
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to perform a ﬁ  nger stick blood sugar on arrival so one can 
cancel before admission.
Patients undergoing minor surgical procedures (e.g., 
arthroscopy) may be brought to the hospital on the morning 
of surgery. As the patient is usually NPO (i.e., has been 
given orders to fast before the surgery), a lower dose of the 
intermediate- or long-acting insulin is administered, and the 
regular insulin is withheld (Box 1). Insulin therapy should 
never be withheld in a patient with type 1 diabetes as this can 
result in DKA.
How Should His Insulin Be Managed before Surgery?
The degree of metabolic control should be carefully 
evaluated before surgery; the goal is to improve the patient’s 
blood glucose readings on an outpatient basis before 
undergoing surgery. If hyperglycemia has been present 
for a prolonged period of time before surgery, this could 
result in dehydration, which is commonly associated with 
electrolytic abnormalities such as sodium and potassium 
loss and possibly intravascular volume depletion. Prolonged 
hyperglycemia will delay healing and increase the risk of 
ischemia. A number of observations have indicated that 
hyperglycemia impairs collagen formation and causes 
a decrease in the tensile strength of surgical wounds 
[1,2]. Simply avoiding hyperglycemia can prevent these 
consequences. The reduction of glucose levels to below 200 
mg/dl has been shown to improve granulocyte adherence 
and granulocytosis, both key components of the innate 
immunity and the defense against bacterial infections. 
Studies in both humans and animals suggest that high 
glucose levels might exacerbate 
ischemic brain damage [3].
Admission to the hospital is 
recommended for all patients with 
type 1 diabetes, and a stabilization 
period of 12–16 hours is also 
recommended for urgent procedures 
if severe hyperglycemia is present 
[4,5]. However, the widespread use 
of home blood glucose monitoring 
makes the improvement of glycemic 
control possible prior to admission. 
Traditionally, long-acting (e.g. 
ultralente) insulin is discontinued 
2–3 days before surgery, and the 
patient is stabilized on a regimen 
of intermediate-acting (neutral 
protamine hagedorn [NPH] or lente) 
and short-acting (regular or humalog) 
insulin twice a day, or regular insulin 
before meals and intermediate-acting 
insulin at bedtime. However, if the 
glycemic control is good and the 
patient is being treated with glargine, 
it is acceptable to continue the 
regimen until the day of surgery [3]. 
Alternatively, 1/2–2/3 of the usual 
insulin regimen is given on the day of 
the procedure [3]. On the morning of 
surgery patients with type 1 diabetes 
should receive the insulin regimen that 
is used intraoperatively (Box 2) [6]. 
Evaluation of metabolic homeostasis, lipid proﬁ  le, and 
kidney and myocardial function must be completed before 
surgery. The presence of diabetic autonomic neuropathy 
should also be assessed prior to surgery because this 
condition predisposes to perioperative hypotension. In such 
patients meticulous monitoring of blood pressure and volume 
status is essential during the perioperative period [7]. 
The common agreement is that 4–8 hours before surgery, 
the patient should be kept NPO, subcutaneous (SC) 
insulin should be discontinued, and an intravenous (IV) 
infusion line should be inserted. It should be emphasized 
that if the elective surgical procedure can be scheduled for 
early morning hours and the procedure lasts at least four 
hours, this limits the NPO to about 4–6 hours and allows 
administration of usual or 1/2–2/3 usual insulin and use of 
a glucose infusion to replace breakfast and supplemental 
insulin either subcutaneously or intravenously. If both 
glucose and insulin are infused, it should be pointed out that 
these must be two separately controlled infusions, so glucose 
and insulin infusion can be varied independently.
How Should His Insulin Be Managed during Surgery?
Major surgery and general anesthesia can cause severe 
metabolic abnormalities in patients with type 1 diabetes. 
Given the limitations of SC insulin therapy, such as 
unpredictable absorption and variable plasma insulin levels, 
constant infusion of insulin is recommended [3]. Anesthesia 
induces complex neuroendocrine stress responses and 
activates the sympathetic nervous system. The abnormal 
release of growth hormone, cortisol, and epinephrine leads 
Box 2. IV Insulin-Glucose Infusion for Surgery
Preoperative Days
Attempt to obtain reasonable glycemic control. The goal is to achieve preprandial 
glycemic levels between 70 and 150 mg/dl (3.9–8.3 mmol/l).
Operative Day
• Four to eight hours before surgery, keep patient NPO, discontinue SC insulin, and 
insert IV infusion line. 
• Measure capillary glucose levels at one-hour intervals.
• Infuse D5W intravenously via an IV regulator pump.
• If renal function and serum potassium concentration are normal, add 20 mEq KCl/l.
• Based on hourly blood glucose determination, adjust each infusion as indicated in 
Table 2.
Modiﬁ  ed from [6].
Table 2. Infusing Insulin-Glucose during Surgery
Blood Glucose Insulin Infusion D5W Infusion (ml/h)
mg/dl mmol/l ml/h units/h
≤70a ≤3.9  1.0  0.5   150
  71–100  3.6–5.6  2.0  1.0   125
  101–150  5.6–8.3  3.0  1.5   100
  151–200  8.3–11.1  4.0  2.0   75
  201–250   11.1–13.9  6.0  3.0   50
  251–300   13.9–16.7  8.0  4.0  0
≥300   ≥16.7   12.0  6.0  0
aAdminister 10 ml D5W intravenously and repeat glycemic levels 15 minutes later.
DOI: 10.1371/journal.pmed.0020140.t002
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to impaired insulin secretion, and causes insulin resistance 
and hyperglycemia due to increased glycogenolysis, 
gluconeogenesis, and decreased glucose disposal. Many other 
conditions may cause severe insulin resistance in a patient 
with diabetes (Box 3).
For patients scheduled for elective surgery, IV insulin 
and glucose infusion are usually started several hours 
preoperatively, and glucose levels should be maintained 
between 100 and 125 mg/dl. Slightly higher targets (100–150 
mg/dl) have been recommended by some diabetologists 
to minimize the risk of hypoglycemia. The maintenance 
of glucose levels below 200 mg/dl has been shown to 
prevent bacterial infections and ischemic brain damage 
[3,8]. Suggested guidelines for management of patients 
with type 1 diabetes by use of insulin are outlined in Box 2. 
Since IV regular insulin has a short half-life (ten minutes), 
hypoglycemia is of little concern, as the infusion can be 
decreased and the IV glucose rate increased. The infusion 
rate can be adjusted by a ﬂ  oor nurse before surgery and by 
the anesthesiologist intraoperatively. An insulin infusion 
algorithm is constructed to allow easy titration of the insulin 
dose, and IV glucose must also be infused to obtain glucose 
levels within target (Box 2). This type of algorithm is effective 
in the majority of patients; however, it is based on the 
“average” patient and might require individualization. If the 
patient has a coexisting condition associated with increased 
insulin requirement, IV insulin doses need to be increased. 
Glycemic levels must be monitored at hourly intervals to keep 
glucose levels between 100 and 125 mg/dl. 
Patients with type 1 diabetes who are treated with 
continuous SC insulin infusion by an insulin pump should 
be easily converted to IV regular insulin infusion just before 
surgery. Continuous SC insulin infusion is an acceptable 
regimen for surgical procedures requiring local anesthesia.
How Should Fluids and Electrolytes Be Managed 
in This Patient?
An adult without diabetes requires a minimum of 100 to 125 
grams (400 to 500 calories) of glucose per day to prevent 
protein catabolism and the development of ketosis. Hence, 
this patient with types 1 diabetes should be treated with 
5–10 grams of glucose per hour (1.2 to 2.4 mg/kg/min in 
a 70-kilogram subject) to provide sufﬁ  cient basal energy 
requirement and prevent hypoglycemia during surgery. 
The dextrose concentration of the IV solution (Box 2) is 
adjusted based on the expected length of surgery. Thus, in 
this case 5% of dextrose in water (D5W) can be administered 
intravenously via infusion pump. For longer surgical 
procedures (intraabdominal or intrathoracic surgery), 
10% of dextrose should be used to avoid excessive ﬂ  uid 
administration. A 20% or 50% dextrose solution can be 
infused through a central venous catheter if ﬂ  uid restriction 
is critical. If additional ﬂ  uids are required, for instance, to 
replace unexpected intraoperative blood losses, non-glucose-
containing solutions should be administered. 
As a general rule, normal serum potassium levels do not 
necessarily imply that the total body potassium content 
is normal, as only 2% of total body potassium stores are 
extracellular [9]. In patients with diabetes, the metabolic 
homeostasis can rapidly be altered and many factors may 
inﬂ  uence serum potassium levels and total body potassium 
stores. These factors are (a) insulin, which increases 
potassium uptake by cells; (b) acidemia, which causes 
hyperkalemia as a result of the exchange of intracellular 
potassium for hydrogen ions; and (c) hyperosmolarity, 
which causes a rearrangement of potassium and ﬂ  uid from 
intracellular to extracellular compartments. In patients 
with diabetes who have normal renal function and normal 
serum potassium concentration, 10 to 20 mEq of potassium 
should be added to each liter of dextrose-containing ﬂ  uid. 
A higher dose is required in patients with hypokalemia. If 
serum potassium levels are greater than 5.5 mEq/l, potassium 
therapy should be withheld from the IV ﬂ  uids and potassium 
serum levels should be monitored closely. 
How Would the Management of This Patient Be 
Different for Emergency Rather Than Elective Surgery?
It has been estimated that as many as 5% of all patients with 
diabetes require surgery at some point during their lives 
[3]. Many of these patients undergo emergency surgery as 
a result of lower extremity infections requiring incision and 
drainage or even lower limb amputations. More than 50% 
of lower limb amputations in the United States occur among 
people with diabetes. The majority of patients with diabetes 
admitted for emergency procedures have a poor glyco-
metabolic control and some of them may have coexisting 
DKA. The ﬁ  rst step in management is to assess glycemic, 
electrolyte, acid-base, and volume status. An IV saline infusion 
should be started while waiting for laboratory tests to correct 
possible volume loss. Insulin infusion should be started at an 
appropriate rate (Box 2), and frequently insulin requirement 
might increase during emergency surgery. It is crucial that 
volume losses and electrolyte abnormalities are corrected 
prior to surgery.
If DKA is diagnosed, immediate treatment is indicated, 
and, if possible, surgery should be delayed until the glyco-
metabolic control is corrected and stabilized. If emergency 
surgery procedures cannot be delayed, DKA can be treated 
concurrently with surgery.
How Should the Postoperative Glyco-Metabolic 
Management Be Handled in This Patient?
Both IV insulin and glucose (D5W, 0.45% normal saline) 
infusion should be continued until the glycol-metabolic 
control is stable and until 1–2 hours after the patient is able 
to resume oral feeding without difﬁ  culty. If postoperative 
nausea and vomiting are present, IV insulin and glucose 
infusion should not be discontinued. Furthermore, in 
patients with type 1 diabetes ketonuria could be an early sign 
of impending DKA, which could be triggered by starvation. 
Capillary glucose should be monitored every 1–2 hours at the 
bedside, and the variable insulin and glucose infusion should 
Box 3. Illnesses and Conditions Frequently 
Associated with Increased Insulin Requirement
• Recent DKA
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be adjusted to maintain blood glucose levels between 100 and 
150 mg/dl (Box 4). Serum electrolytes should be measured 
immediately after surgery. Hypo- and hyperkalemia are fairly 
common in the postoperative period and should be corrected 
without delay. The presence of a widened anion gap suggests 
the possibility of DKA or lactic acidosis that might be caused 
by systemic infections or hypoperfusion.
If the patient is stable and can tolerate oral feeding, the 
regular home dose of insulin may be administered 20–30 
minutes before the meal and the insulin infusion stopped 15–
20 minutes after the meal. Of note, insulin infusion should be 
discontinued only after the SC insulin regimen is started to 
avoid any gaps in plasma insulin levels that may lead to a loss 
of metabolic control. 
Resuming a sliding scale SC insulin treatment 
postoperatively has been advocated to improve metabolic 
control in patients with type 1 diabetes. However, there 
are several drawbacks with this approach. First of all, 
this approach is based on a retrospective treatment for 
hyperglycemia, which reﬂ  ects the degree of insulin sensitivity 
and glucose disposal rate in the preoperative period. The 
use of a SC insulin treatment postoperatively tends to create 
ﬂ  uctuations in blood glucose levels that could be difﬁ  cult 
to control. Moreover, there is a risk of exposing the patient 
to the risk of hypoglycemia if excessive doses of insulin are 
administered. More importantly, the use of a sliding scale 
treatment might predispose to DKA in insulin-deﬁ  cient 
patients before the development of hyperglycemic levels.
What Are the General Principles for Surgery 
in a Patient with Type 2 Diabetes?
Patients with type 2 diabetes require good blood glucose 
control prior to undergoing surgery. Although these 
patients seldom develop DKA, the same adverse effects of 
poor glycemic control may develop. For procedures that 
require general anesthesia, speciﬁ  c treatment, other than 
hourly glycemic monitoring, is not required for patients with 
type 2 diabetes whose diabetes is well controlled with diet 
(i.e., fasting blood glucose less than 125 mg/dl). However, 
insulin should still be administered as described in Box 2, as 
hyperglycemic responses may still occur intraoperatively in 
these patients. Targeted glycemic levels are identical to those 
for patients with type 1 diabetes. For elective procedures 
requiring general anesthesia, insulin infusion is usually 
required to control hyperglycemic levels that occur during 
surgery. Frequent intraoperative glucose monitoring is 
imperative in this setting to avoid complications resulting 
from a poor glycemic control. Patients with type 2 diabetes 
who require insulin and who are scheduled for surgery 
should be managed similarly to patients with type 1 diabetes.
As a general rule, SC insulin should not be used in patients 
with type 2 diabetes requiring surgery and general anesthesia, 
since insulin absorption from the SC tissue could be quite 
variable, particularly in obese individuals.  
With regard to patients with type 2 diabetes who require 
general anesthesia and whose diabetes is well controlled with 
sulfonylureas, there is some degree of disagreement. Many 
diabetologists recommend withholding the sulfonylurea the 
morning of surgery for procedures requiring general or local 
anesthesia and using continuous insulin infusion. 
Any patient treated with metformin should discontinue 
this medication at least 48 hours before surgery. The drug 
should be completely cleared after discontinuing metformin 
48 hours preceding surgery. This is a prophylactic measure 
in an effort to lower the risk of lactic acidosis that could be 
secondary to complications of surgical procedures such as 
hypotension, myocardial infarction, or septic shock.
Treatment decisions for patients with type 2 diabetes 
receiving local anesthesia and undergoing minor surgical 
procedures are similar to those described above for patients 
with type 1 diabetes. 
DISCUSSION
Patients with type 1 diabetes undergoing elective or 
emergency surgical procedures have a higher degree of 
morbidity and mortality than those without diabetes, as 
a result of impaired glyco-metabolic homeostasis and 
electrolyte balance. The magnitude of the catabolic responses 
is not only related to the severity of surgical and postsurgical 
complications but also to the effects of inadequate 
perioperative management on metabolic control. Health-
care providers should be very familiar with the perioperative 
management of type 1 diabetes; with individualized insulin 
and glucose variable infusions, young patients affected by type 
1 diabetes can undergo surgery with a minimal risk. 
The goal of glycemic management in these situations 
is to maintain normal glucose homeostasis and normal 
metabolism. As insulin resistance and gluconeogenesis 
increase during surgery-related stress and anesthesia, 
Box 4. Type 1 Diabetes Management after Surgery
• Continue IV insulin and glucose (D5W) infusion until two hours 
after oral feeding is resumed.
• Measure capillary blood glucose before meals, at 10:00 p.m., 
and at 3:00 a.m.a
• Maintain blood glucose levels between 100 and 150 mg/dl 
(5.5–8.3 mmol/l).
• Provide three meals and three snacks (20–30 kcal/kg/day).
• Administer preprandial short- or fast-acting insulin 
subcutaneously according to the schedule in Table 3.
• For patients treated with continuous SC insulin infusion, resume 
basal rate and give bolus doses according to the carbohydrate 
counts. 
aIf hypoglycemia is present at 3:00 a.m., reduce the 10:00 p.m. 
insulin dose.
Modiﬁ  ed from [6].
Table 3. Administering Insulin after Surgery
Blood Glucose Short- or Fast-Acting Insulin (Units)
mg/dl   mmol/l Breakfast Lunch Dinner 10:00 
p.m.
≤70   ≤3.9  3  2  2  0
  71–100  3.6–5.6  4  3  3  0
  101–150  5.6–8.3  6  4  4  0
  151–200  8.3–11.1  8  6  6  0
  201–250   11.1–13.9   10  8  8  1
  251–300  13.9–16.7  12  10  10   2
≥300  ≥16.7  14  12  12   3
DOI: 10.1371/journal.pmed.0020140.t003
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additional insulin will be needed to prevent excessive 
hepatic glucose release. An important issue is maintaining a 
physiological ﬂ  uid and electrolyte balance. 
Perioperative hyperglycemia increases the risk of infections, 
delayed wound healing, and ischemia. Achieving preprandial 
glycemic levels between 70 and 150 mg/dl before surgery 
in the preoperative period and maintaining plasma glucose 
levels between 100 and 125 mg/dl during surgery and 
between 100 and 150 mg/dl after surgery using simple and 
safe algorithms (Boxes 1, 2, and 4) can signiﬁ  cantly decrease 
the risk of these complications.  
References 
1.  Marhoffer W, Stein M, Maeser E, Federlin K(1992) Impairment of 
polymorphonuclear leukocyte function and metabolic control of diabetes. 
Diabetes Care 15: 256–260.
2.  Rosenberg CS (1990) Wound healing in the patient with diabetes mellitus. 
Nurs Clin North Am 25: 247–261.
3.  Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, et al. (2004) 
Management of diabetes and hyperglycemia in hospitals. Diabetes Care 27: 
553–591.
4.  van den Berghe G, Wouters, P, Weekers F, Verwaest C, Bruyninckx F, et al. 
(2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 
345: 1359–1367.
5.  Avilès-Santa L, Raskin P (2004) Surgery and anesthesia. In: Lebovitz HE, 
editor. Therapy for diabetes mellitus and its related disorders. Alexandria 
(Virginia): American Diabetes Association/Port City Press. pp. 247–258.
6.  Rosenstock J, Raskin P (1987) Surgery! Practical guidelines for diabetes 
management. Clin Diabetes 5: 61.
7.  Burgos LG, Ebert TJ, Asiddao C, Turner LA, Pattison CZ, et al. (1989) 
Increased intraoperative cardiovascular morbidity in diabetics with 
autonomic neuropathy. Anesthesiology 70: 591–597.
8.  Gill GV, Alberti KGMM (1997) The care of the diabetic patient 
during surgery. In: Alberti KGMM, Zimmet PZ, DeFronzo RA, editors. 
International textbook of diabetes mellitus. Chichester (United Kingdom): 
Wiley. pp. 1243–1254.
9.  Levetan CS, Magee MF (2000) Hospital management of diabetes. 
Endocrinol Metab Clin North Am 29: 745–770.
Key Learning Points
• Patients with type 1 diabetes undergoing elective or 
emergency surgical procedures have a higher degree of 
morbidity and mortality than those without diabetes.
• Perioperative hyperglycemia is associated with an increased risk 
of infections, delayed wound healing, and an increased risk of 
ischemia.
• A patient with poorly controlled diabetes should not undergo 
elective surgery until glycemic levels are reasonably controlled.
• Patients undergoing minor surgical procedures, such as 
arthroscopy, may be brought to the hospital on the morning of 
surgery.
• Given the limitations of subcutaneous insulin therapy, such 
as unpredictable absorption and variable plasma insulin levels, 
constant infusion of insulin is recommended during surgery.
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